Current Perspective in the Diagnosis and Treatment of Adrenocortical Carcinoma

Reviews in Endocrine and Metabolic Disorders

Volumn 2, Issue 3, 2001, Pages 323-333

  Schteingart, David E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chromosome abnormalities; Imaging; Mitotane; Mitotic rate; Staging; Steroids; Surgical excision; Tumor size

Indexed keywords

ADRENAL CORTEX TUMOR; ADULT; AGED; CANCER STAGING; CASE REPORT; FEMALE; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PATHOLOGY; REVIEW;

ADRENAL CORTEX NEOPLASMS; ADULT; AGED; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING;

EID: 0035431634     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011576702293     Document Type: Article

References (57)

1. Brennan MF. Adrenocortical carcinoma. Ca - A Cancer Journal for Clinicians 1987;37(6):348-365.
2. Figueiredo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovski MA, Giatzakis C, Young HM, Haddad BR. Comparative genomic hybridization analysis of adrenocortical tumors in childhood. J Clin Endocrinol & Metab 1999;84(3):1116-1121.
3. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: Recent advances in basic concepts and clinical management. Ann Intern Med 1999;130(9):759-771.
4. Grayson GH, Moore S, Schneider BG, Saldivar V, Hensel CH. Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma. Am J Pediatr Hematol Oncol 1994;16(4):341-347.
5. Lin SR, Lee YJ, Tsai JH. Mutations of the p53 gene in human functional adrenocortical neoplasms. J Clin Endocrinol Metab 1994;78:483-491.
6. Miyamoto H, Kubota Y, Shuin T, Shiozaki H. Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and RB gene loci. Cancer Genet Cytogenet 1996;88(2):181-183.
7. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, Chrousos GP. p53 mutations in human adrenocortical neoplasms; Immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994;78(3):790-794.
8. McNicol AM, Nolan CE, Struthers AJ, Farquharson MA, Hermans J, Haak HR. Expression of p53 in adrenocortical tumours: Clinicopathological correlations. J Pathol 1997;181:146-152.
9. Lynch HT, Katz DA, Bogard PJ, Lynch JF. The sarcoma, breast cancer, lung cancer and adrenocortical carcinoma syndrome revisited. Childhood cancer. Am J Dis Child 1985;139(2):134-136.
10. Schteingart DE. Treating adrenal cancer. The Endocrinologist 1992;2:149-157.
11. Grondal S, Curstedt T. Steroid profile in serum: Increased levels of sulphated pregnenolone and pregn-5-ene-3 beta, 20 alpha-diol in patients with adrenocortical carcinoma. Acta Endocrinol 1991;124(4):381-385.
12. Farge D, Chatellier G, Pagny JY, Jeunemaitre X, Plouin PF, Corvol P. Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma. Am J Med 1987;83(4):635-640.
13. Arteaga E, Biglieri EG, Kater CE, Lopez JM, Schambelan M. Aldosterone-producing adrenocortical carcinoma. Preoperative recognition and course in three cases. Ann Intern Med 1984;101(3):316-321.
14. Hamper UM, Fishman EK, Hartman DS, Roberts JL, Sanders RC. Primary adrenocortical carcinoma: Sonographic evaluation with clinical and pathologic correlation in 26 patients. Am J Roentgenol 1987;148(5):915-919.
15. Smith SM, Patel SK, Turner DA, Matalon TA. Magnetic resonance imaging of adrenal cortical carcinoma. Urol Radiology 1989;11(1):1-6.
16. Korobkin M, Lombardi TJ, Aisen AM, Francis IR, Quint LE, Dunnick NR, Londy F, Shapiro B, Gross MD, Thompson NW. Characterization of adrenal masses with chemical shift and Gadolinium enhanced imaging. Radiology 1995;197:414-418.
17. Gross MD, Shapiro B, Bouffard J, Glazer GM, Francis IR, Wilton GP, Khafagi F, Sonda LP. Distinguishing benign and malignant euadrenal masses. Ann Intern Med 1988;109:613-618.
18. Weiss LM. Comparative histologic study of 43 metastasizing and non-metastasizing adrenocortical tumors. Am J Surg Path 1984;8: 163-169.
19. Medeiros LJ, Weiss LM. New development in the pathologic diagnosis of adrenal cortical neoplasms - A review. Am J Clin Path 1991;97:73-83.
20. Fetsch PA, Powers CN, Zakowski MF, Abati A. Anti-alpha-inhibin: Marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine needle aspiration. Cancer 1999;87(3):168-172.
21. Cibas ES, Medeiros LJ, Weinberg DS, Gelb AB, Weiss LM. Cellular DNA profiles of benign and malignant adrenocortical tumors. Am J Surg Pathol 1990;13:202-206.
22. MacFarlane DA. Cancer of the adrenal cortex: The natural history, prognosis and treatment in the study of fifty five cases. Ann R Coll Surg Engl 1958;23:155-186.
23. Sullivan M. Adrenal cortical carcinoma. Urology 1978;120:660.
24. Hogan T. A clinical and pathological study of adrenocortical carcinoma; therapeutic implications. Cancer 1980;45:2880.
25. Bradley E. Primary and adjunctive therapy in carcinoma of the adrenal cortex. Surg Gynecol Obstet 1975;141:507.
26. Thompson NW. Adrenocortical carcinoma. Endocrine Surgery Update. Thompson NW, Vinik AI, eds. 1983;119-128.
27. Peix JL, Mancini F, Villard J, Van Box Som P. Malignant corticoadrenal tumors with vena cava extension. Is surgical resection justified? Annales de Chirurgie 1998;52(4):357-363.
28. Bodie B, Novick AC, Pontes JE, Straffon RA, Montie JE, Babiak T, Sheeler L, Schumaker P. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989;141(2):257-260.
29. Percarpio B, Knowlton AH. Radiation therapy of adrenal cortical carcinoma. Acta Rad Ther 1976;15:288-292.
30. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;3322(17):1195-1201.
31. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotnae and a review of the literature. Cancer 1993;72:3145-155.
32. Haak HR, Hermans J, VandeVelde CJH, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. Optimal treatment of adrenal cortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Brit J Cancer 1994;69(5):947-951.
33. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogilotti L, Angeli A. Low dose monitored mitotane treatment achieves therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000;85(6):2234-2238.
34. VanSeters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol 1991;124(5):526-533.
35. Martz F, Straw JA. The in vitro biotransformations of 1-(o-chlorophenyl)-1-(chlorophenyl)-2,2-dichloroethane (o,p′-DDD) by dog adrenal mitochondria macromolecules. Drug Metab Dispos 1977;5:482-486.
36. Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL, Fojo AT. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-l/p-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991;73(1):18-29.
37. Schteingart DE, Sinsheimer JE, Counsell RE, Abrams GD, McClellan N, Djanegara T, Hines J, Ruangwises N, Benitez R, Wotring LL. Comparison of adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemother Pharmacol 1993;31:459-466.
38. Cai W, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL. The metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 1995;84:134-138.
39. 3H-mitotane for use in a rapid assay for mitotane metabolism. J Labeled Compds 1995;36:121-127.
40. Kasperlik-Zaluska A. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical carcinoma. Cancer 1994;73:1533-1534.
41. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119-3123.
42. Dickstein G, Schechner C, Arad E, Best LA, Nativ O. Is there a role for low dose mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma. J Clin Endocrinol Metab 1999;84(4):1488-1489.
43. Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C. 5-Fluorouracil, doxorubicin and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991;67(12):2997-3000.
44. Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986;58:2198-2202.
45. Beruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the study of adrenal cancer. Cancer 1998;83(10):2194-2200.
46. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma. A southwestern oncology study. Cancer 2000;88(5):1159-1165.
47. La Rocca RV, Stein CA, Danesi R, Jamis-Dow CA, Weiss GH, Myers CE. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990;71(2):497-504.
48. Fallo F, Pilon C, Barzon L, Pistorello M, Pagotto U, Altavilla G, Boscaro M, Sonino N. Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line. Endocrine Research 1996;22(4):709-715.
49. Fallo F, Pilon C, Barzon L, Pistorello M, Pagotto U, Altavilla G, Boscaro M, Sonino N. Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy 1998;44(2):129-134.
50. Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma: Aggressive resection vs. chemotherapy. Arch Surg 1991;126(4): 457-461.
51. King D, Lack E. Adrenal cortical carcinoma; a clinical and pathological study of 49 cases. Cancer 1979;44:239.
52. Bradley EL. Primary and adjunctive therapy in carcinoma of the adrenal cortex. Surg Gynecol Obstet 1975;141(4):507-516.
53. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1988;13:202-206.
54. Gaboardi F, Carbone M, Bozzola A, Galli L. Adrenal incidentalomas: What is the role of fine needle biopsy. Int Urol Nephrol 1991;23:197-207.
55. Kruimel JW, Smals AG, Beex LU, Swinkels LM, Pieters GF, Kloppenborg PW. Favourable response of a virilizing adrenocortical carcinoma to preoperative treatment with ketoconazole and postoperative chemotherapy. Acta Endocrinol 1991;124(4):492-496.
56. Contreras P, Rojas A, Biagini L, Gonzalez P, Massardo T. Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet 1985;2:151.
57. Schteingart DE, Cash R, Conn JW. Aminoglutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome. JAMA 1966;198:1007.